Postcovid syndrome in patients with inflammatory bowel diseases
DOI: 10.32364/2587-6821-2022-6-5-227-231
L.M. Kupkenova1, N.G. Shamsutdinova1, A.Kh. Odintsova2, N.A. Cheremina2, D.G. Iskhakova3, D.I. Abdulganieva1
1Kazan State Medical University, Kazan, Russian Federation
2Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation
3City Clinical Hospital No. 7, Kazan, Russian Federation
Aim: to assess the presence and course of postcovid syndrome in patients with inflammatory bowel diseases (IBD), as well as to study the IBD course in the postcovid period.
Patients and Methods: 125 patients with Crohn’s disease (CD) and ulcerative colitis (UC) in the postcovid period were sequentially included in the study. Assessment of the postcovid syndrome was conducted 3, 6, 9 or 12 months after acute period of COVID-19. A questionnaire included in an in-depth medical check-up for citizens who have experienced COVID-19 was used to identify the clinical symptoms of postcovid syndrome. The article presents the results of the following scales: Hospital Anxiety and Depression Scale (HADS) — to identify and evaluate the severity of depression and anxiety, Hamilton Depression Rating Scale (HAM-D) — to evaluate depression, Asthenic State Scale (ASS) — to diagnose asthenic condition, Mini Mental State Examination (MMSE) — to study the severity of cognitive disorder. The nature of the IBD course and the change in therapy were also evaluated.
Results: 81 (64.8%) patients were diagnosed with CD, and 44 (35.2%) — with UC. The mean age of patients was 41.8±14.5 years, of which 68 (54.4%) were male, 57 (45.6%) — female. When filling up the questionnaire of the in-depth medical check-up 3 months after COVID-19, 47.8% of patients most commonly noted fatigue, and/or muscle pain, and/or headaches, and/or dysautonomia, and/or cognitive disorder, while 34.7% of patients — dyspnea, reduced exercise tolerance and/or chronic cough, and joint pain. Thus, postcovid manifestations occurred in approx. 47.8% of patients with IBD. An increase of complaints frequency, characteristic of postcovid syndrome, was noted by the 6th month after COVID-19. By the 9th and 12th month, the frequency of complaints decreased. When analyzing complaints related to asthenia, cognitive disorder, anxiety and depression, there was a tendency to the maximum number of disorders 6 months after COVID-19. Studying the activity in patients with IBD before, during and after COVID-19 (after 3, 6, 9 or 12 months), it was noted that the largest number of patients with acute IBD was 6 months after COVID-19.
Conclusions: 47% of patients with IBD had complaints characteristic of postcovid syndrome, which persisted up to 12 months after COVID-19. Asthenia was the most common. Several complaints were increasing by the 6th month. IBD exacerbation rate reached its maximum value also by the 6th month after COVID-19.
Keywords: inflammatory bowel diseases, ulcerative colitis, Crohn’s disease, new coronavirus infection, COVID-19, postcovid syndrome, anxiety, depression, cognitive disorder, asthenia.
For citation: Kupkenova L.M., Shamsutdinova N.G., Odintsova A.Kh. et al. Postcovid syndrome in patients with inflammatory bowel diseases. Russian Medical Inquiry. 2022;6(5):227–231 (in Russ.). DOI: 10.32364/2587-6821-2022-6-5-227-231.
About the authors:
Lyutsia M. Kupkenova — Associate Professor of the Department of Hospital Therapy, Kazan State Medical University; 49, Butlerov str., Kazan, 420012, Russian Federation; ORCID iD 0000-0003-2874-9462.
Nailya G. Shamsutdinova — C. Sc. (Med.), Associate Professor of the Department of Hospital Therapy, Kazan State Medical University; 49, Butlerov str., Kazan, 420012, Russian Federation; ORCID iD 0000-0001-7320-0861.
Alfiya Kh. Odintsova — C. Sc. (Med.), Head of the Department of Gastroenterology, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan; 138/1, Orenburg tract, Kazan, 420064, Russian Federation; ORCID iD 0000-0002-7148-8862.
Natalia A. Cheremina — gastroenterologist, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan; 138/1, Orenburg tract, Kazan, 420064, Russian Federation; ORCID iD 0000-0002-5856-5050.
Dilyara G. Iskhakova — Head of the Department of Gastroenterology, City Clinical Hospital No. 7; 54, Marshal Chuikov str., Kazan, 420103, Russian Federation; ORCID iD 0000-0003-3829-5302.
Diana I. Abdulganieva — Dr. Sc. (Med), Professor, Head of the Department of Hospital Therapy, Kazan State Medical University; 49, Butlerov str., Kazan, 420012, Russian Federation; ORCID iD 0000-0001-7069-2725.
Contact information: Lyutsia M. Kupkenova, e-mail: lkupkenova@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
Funding source: the work was conducted within the framework of the Grant of the President of the Russian Federation to support the leading scientific schools of the Russian Federation (НШ-4321.2022.3).
There is no conflict of interests.
Received 07.04.2022.
Revised 04.05.2022.
Accepted 31.05.2022.
2. Crook H., Raza S., Nowell J. et al. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. DOI: 10.1136/bmj.n1648.
3. Salvatori S., Baldassarre F., Mossa M., Monteleone G. Long COVID in Inflammatory Bowel Diseases. J Clin Med. 2021;10(23):5575. DOI: 10.3390/jcm10235575.
4. Ivashkin V.T., Shelygin Yu.A., Belousova E.A. et al. Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2(72)):8–38 (in Russ.). DOI: 10.33878/2073-7556-2020-19-2-8-38.
5. Ivashkin V.T., Shelygin Yu.A., Belousova E.A. et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4(70)):7–36 (in Russ). DOI: 10.33878/2073-7556-2019-18-4-7-36.
6. Interim guidelines for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 15 (22.02.2022) (in Russ.).
7. Order of the Ministry of Health of the Russian Federation dated July 1, 2021 No. 698n "On approval of the procedure for sending citizens to undergo in-depth medical examination, including categories of citizens undergoing in-depth medical examination as a matter of priority" (Registered on July 7, 2021 No. 64157) (in Russ.).
8. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. DOI: 10.1111/j.1600-0447.1983.tb09716.x.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. DOI: 10.1136/jnnp.23.1.56.
10. Zolotovskaia I.A., Shatskaia P.R., Davydkin I.L., Shavlovskaya O.A. Post-COVID-19 asthenic syndrome. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(4):25–30 (in Russ.). DOI: 10.17116/jnevro202112104125.
11. Min-mental status assessment scale (MMSE) (Electronic resource.) URL: https://memini.ru/tests/23789/ (access date: 23.01.2022).
12. Finney G.R., Minagar A., Heilman K.M. et al. Postdischarge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4–e6. DOI: 10.1016/j.jinf.2020.08.029.
13. Silva Andrade B., Siqueira S., de Assis Soares W.R. et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021;13(4):700. DOI: 10.3390/v13040700.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать